No. |
DrugBank |
薬物名(臨床試験情報から抽出) |
KEGG DRUG * | KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 | Calcium | 25件: Amorphous calcium carbonate; Ascal(r) / carbasalate calcium; Atorvastatin calcium; Calcitriol & calcium; Calcium; Calcium and cholecalciferol; Calcium carbonate; Calcium carbonate and alphacalcidol; Calcium channel blockers; Calcium channel blockers (amlodipine, azelnidipine); Calcium citrate; Calcium citrate with vitamin d2; Calcium gluconate; Calcium lactate; Calcium levofolinate; Calcium rosuvastatin; Calcium, dietary; Carbasalate calcium; Crestor tablets (calcium rosuvastatin) film-coated tablets; Crystalline calcium supplements; Ibandronate+alfacalcidol+calcium; Low molecular weight heparin calcium injection; Rosuvastatin calcium; Symptomatic treatment (converting enzyme inhibitor, angiotensin ii, anti-renin, aldosterone antagonist diuretic, beta blocker, calcium inhibitor, statin); Vidofludimus calcium; | - |
- |
- |
24件: 6, 13, 19, 46, 49, 51, 65, 68, 75, 79, 84, 93, 94, 95, 96, 97, 214, 215, 222, 224, 235, 265, 298, 299 |
2 | Calcium gluconate | 1件: Calcium gluconate; | D00935 |
- |
- |
3件: 214, 215, 235 |
3 | Dexmedetomidine | 8件: Dexmedetomidine; Dexmedetomidine 1; Dexmedetomidine 2; Dexmedetomidine 3; Dexmedetomidine and fentanyl; Dexmedetomidine group; Dexmedetomidine hydrochloride; Dexmedetomidine hydrochloride infusion; | D00514 D01205 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
11件: 2, 4, 6, 21, 34, 70, 113, 212, 215, 226, 280 |
4 | Dobutamine | 1件: Dobutamine; | D00632 D03879 D03880 D03881 |
1件: ADRB1 |
10件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
3件: 57, 58, 215 |
5 | Eplerenone | 1件: Eplerenone; | D01115 |
1件: NR3C2 |
1件: Aldosterone-regulated sodium reabsorption |
3件: 75, 113, 215 |
6 | Fentanyl | 5件: Dexmedetomidine and fentanyl; Fentanyl; Fentanyl citrate; Fentanyl transdermal patch; Transdermal fentanyl matrix, gabapentin; | D00320 D01399 |
1件: OPRM1 |
3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
5件: 46, 70, 85, 215, 231 |
7 | Fluorescein | 1件: Fluorescein; | D01261 D02024 |
- |
- |
3件: 19, 97, 215 |
8 | Ketamine | 3件: Ketamine; S-ketamine; S-ketamine & midazolam; | D00711 D08098 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
6件: 6, 13, 70, 113, 156, 215 |
9 | Losartan | 8件: Lisinopril, losartan, and atorvastatin; Losartan; Losartan and atenolol or propranolol; Losartan bluefish 50 mg; Losartan potasico; Losartan potassium; Losartan tablets & qingremoshen granule; Sildenafil and losartan; | D00357 D08146 |
1件: AGTR1 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
18件: 13, 17, 19, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
10 | Potassium | 4件: Losartan potassium; Potassium; Potassium sparing diuretic; Potassium supplement; | D08403 |
- |
- |
9件: 46, 66, 67, 98, 115, 167, 179, 215, 235 |
11 | Sodium citrate | 1件: Sodium citrate; | D01781 D05855 |
- |
- |
3件: 214, 215, 235 |
12 | Tranexamic acid | 2件: Tranexamic acid; Tranexamic acid 100 mg/ml; | D01136 |
1件: PLG |
4件: Complement and coagulation cascades, Influenza A, Neuroactive ligand-receptor interaction, Staphylococcus aureus infection |
5件: 46, 70, 215, 227, 288 |
13 | Ubidecarenone | - | D01065 |
- |
- |
12件: 2, 5, 6, 8, 10, 46, 57, 86, 113, 193, 214, 215 |